Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Mar 19;12(1):1729.
doi: 10.1038/s41467-021-21950-6.

Reply to 'Are atrial human pluripotent stem cell-derived cardiomyocytes ready to identify drugs that beat atrial fibrillation?'

Assad Shiti  1 , Idit Goldfracht  1 , Naim Shaheen  1 , Stephanie Protze  2 , Lior Gepstein  3   4
Affiliations
Comment

Reply to 'Are atrial human pluripotent stem cell-derived cardiomyocytes ready to identify drugs that beat atrial fibrillation?'

Assad Shiti et al. Nat Commun. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

S.P. has an active consulting agreement with BlueRock Therapeutics LP and received funding from sponsored research agreements with BlueRock Therapeutics LP. The remaining authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Effect of vernakalant on APD in hiPSC-derived atrial cell sheets.
A Example of optical action potentials acquired from the two-dimensional hiPSC-derived atrial cell sheets at baseline (top) and following treatment with 30 µM vernakalant (bottom). Notice the atrial-like triangular-shaped optical action potential morphologies and the longer APD after the drug treatment. B APD80 color-coded maps depicting APD80 values at each pixel of the atrial cell sheets at baseline (top) and following vernakalant treatment (bottom). C Summary of mean APD80 values at baseline and upon administration of 30 µM vernakalant. Note the significant (**P = 0.0074, two-sided paired t test, n = 6) APD80 prolongation (from 115 ± 12 to 168 ± 20 ms) following the drug treatment. Source data is provided as a Source data file.
See this image and copyright information in PMC

Comment on

References

    1. Goldfracht I, et al. Generating ring-shaped engineered heart tissues from ventricular and atrial human pluripotent stem cell-derived cardiomyocytes. Nat. Commun. 2020;11:75. doi: 10.1038/s41467-019-13868-x. - DOI - PMC - PubMed
    1. Lee JH, Protze SI, Laksman Z, Backx PH, Keller GM. Human pluripotent stem cell-derived atrial and ventricular cardiomyocytes develop from distinct mesoderm populations. Cell Stem Cell. 2017;21:179–194 e174. doi: 10.1016/j.stem.2017.07.003. - DOI - PubMed
    1. Zimmermann WH, et al. Tissue engineering of a differentiated cardiac muscle construct. Circ. Res. 2002;90:223–230. doi: 10.1161/hh0202.103644. - DOI - PubMed
    1. Christ, T., Lemoine, M. D. & Eschenhagen, T. Are atrial human pluripotent stem cell-derived cardiomyocytes ready to identify drugs that beat atrial fibrillation? Nat. Commun. 10.1038/s41467-021-21949-z (2021). - PMC - PubMed
    1. Roy D, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117:1518–1525. doi: 10.1161/CIRCULATIONAHA.107.723866. - DOI - PubMed

Substances